Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAD and MAD Study of BBT002 in Healthy Volunteers, COPD, and CRSwNP
NCT06944925Phase 1Recruiting
- Sponsor
- Bambusa Therapeutics
- Start
- May 2025
- Primary completion
- Jan 2027
- Modality
- Bispecific Antibodies
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial of BBT002 in chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP) (14 arms), sponsored by Bambusa Therapeutics. Primary endpoints: Number of participants with adverse events up to 169 days, Number of participants with change in Laboratory assessments up to 169 days and 3 more. Started May 2025; status: recruiting.
02
Drugs
BBT002
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06944925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06944925.